Yes but she relapsed afterward which is why this is a case study for CHECKvacc, there is mentioned of pseudo progression for CF33 as seen in the VAXINIA clinical trial so similar to what was observed.
"However, despite anti-tumor response after sequential treatment with CHECKvacc and T-DXd, the subject experienced relapse after 10 months of PFS"
"To date, no CR in a patient with HER2-zero metastatic BC receiving T-DXd has been reported. In the DESTINY-Breast04 trial targeting HER-2 low BC, only 3.6% of patients in the T-DXd group achieved CR.15No patients achieved CR in the HER2-zero cohort of the DAISY trial, although this could be due to limited sample size (N = 37)"
IMU Price at posting:
3.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)